Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

US 10562953

GPR156 variants and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10561126

Genetically modified non-human animals and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10550193

Methods and antibody compositions for tumor treatment

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10550192

Antigen-binding proteins that antagonize leptin receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10548302

Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrop

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10544232

Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10532096

Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10526403

Anti-activin A antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10526344

Amino acid acylation reagents and methods of using the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10525106

Angiopoietin-based interventions for treating cerebral malaria

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10525104

Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colo

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10524458

Humanized C3 animals

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10519240

Anti-FGFR1c antibody-FGF21 fusion proteins

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10519230

Nucleic acids encoding IL-33 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10513557

Anti-ASIC1 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10501526

Human antibodies to Ebola virus glycoprotein

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10494442

Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10492477

Humanized C5 animals

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10485844

Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10472425

Stabilized formulations containing anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10463749

Maytansinoid derivatives, conjugates thereof, and methods of use

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10464992

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10463748

Human antibodies to S. aureus Hemolysin A toxin

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10463028

Genetically modified non-human animals expressing human EPO

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)